| |  | | May 6, 2024 |  | Luke Lango
Editor, Hypergrowth Investing | | 
Artificial intelligence is all the rage these days. And with good reason. AI will change the world over the next few years. As it does, AI stocks will soar and mint small fortunes for prescient investors.
But, believe it or not, you may be looking at the wrong AI stocks to buy if you’re following the crowd or listening to the mainstream media.
You see – most of the hype these days in the AI Boom has been centered around chipmakers like Nvidia (NVDA) and software companies like Microsoft (MSFT). Those the AI stocks that CNBC and Bloomberg are writing about every day. Those are the AI stocks making all the headlines. Those are the AI stocks your buddies are talking about.
But they are not the AI stocks with the most explosive upside potential over the next few years as the AI Boom rages on…
Rather, that title belongs to a different type of AI stock where a perfect storm is brewing for potentially staggering gains in a short amount of time.
I’m talking about biotech stocks.
Seriously. Biotech stocks. They’re on fire right now.
So far this year, a tiny biotech named Elevation Oncology (ELEV) is up more than 600%. Skye Bioscience (SKYE) is up nearly 380%, and Corbus Pharmaceuticals (CRBP) is up more than 525%. Meanwhile, the S&P 500 is up less than 10% this year.  The biggest AI bull market right now is playing out in biotech stocks.
And it’ll be that way for the foreseeable future, too.
Why? Because a perfect storm is brewing in the overlap of AI and biotechnology.
In part, it’s thanks to AI. And considering that this powerful emerging technology is still in its infancy, we think there’s a ton of room for these stocks to run. | | | | sponsored  Luke Lango, the man who picked Tesla before it sky-rocketed 1,000%+, has traveled all the way to the Tesla Gigafactory in Texas to reveal Elon’s hidden AI project.
It’s known as “AI 2.0”, and in Elon’s own words, it will be “a fundamental transformation for civilization as we know it.”
And even though “AI 2.0” is not yet known, or available to the general public, Luke Lango has found a “backdoor” method to claim a stake before it goes mainstream.
And with the way things are progressing, this wealth window could create a slew of millionaires among those who act before the announcement.
It’s not X.AI, ChatGPT, Grok or any other AI stock, for that matter. Discover How to Claim a Stake in Elon’s 'AI 2.0' Project | | | | It’s All About the Data AI’s application in biology holds the potential to unlock enormous economic value for one simple reason: data.
The more data, the better the AI.
And when it comes to the human body, there is no dearth of quality data. In fact, there is more high-quality data than anywhere else on Earth.
That’s because, like computers, humans are really nothing more than a bunch of data strung together.
At their core, computers are just a bunch of 1s and 0s coded in sequence, with each number corresponding to a certain action for the computer to perform. Humans, similarly, are a bunch of As, Gs, Cs, and Ts strung together – or the four base types found in human DNA molecules – with each determining a person’s characteristics, traits, and even actions.  Humans are full of data.
Apply AI to all that data, and you will change the world. Revolutionizing Medicine With AI The human body has proven to be quite a complex thing. There’s certainly no scarcity of illness or disease that impact folks around the world. And while humanity has made great strides in discovering treatments and cures, countless afflictions remain a reality.
But AI has the potential to solve the myriad problems that plague all humans.
Consider this: It takes about $900 million and 13.5 years to develop a new successful drug.
The drug development process is so expensive and time-consuming that firms cannot afford to push that many drugs forward. This creates a huge shortage in drug candidates and programs relative to what is possible given all the permutations of human biological data.
But AI can significantly shorten and cheapen this process.
Why does it take so long to find new drugs? Because the universe of biological data is enormous. It takes scientists great effort to sort through all the data, uncover the root causes of diseases, and formulate compounds to fight those diseases.
But AI can automate that entire process. It can map out genetic data, identify mutations, and run simulations to find the right compounds and combat those mutations – all almost instantly.
Essentially, researchers can use AI to find new drug candidates much faster than is currently possible.
And this is already happening.
Last year, Japanese pharma giant Takeda Pharmaceutical (TAK) bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using AI.
It isn’t alone.
Other pharma giants like Bayer, Roche, Sanofi (SNY) and AstraZeneca (AZN) are actively using AI technology for drug discovery purposes.
The future of AI-powered drug discovery starts now.
This is big business.
| | | | sponsored  See why the Swan brothers believe early-bird investors in this tiny sub-$5 stock… could fast-track their dream retirement over the next 24 to 36 months. Go Here for Details | | | The Final Word Research firm Deep Pharma Intelligence estimates that investments in the field of AI-powered drug discovery have tripled over the past four years to nearly $25 billion.
Morgan Stanley believes this tech will lead to an additional 50 novel therapies being brought to market over the next decade, with annual sales in excess of $50 billion!  In other words, a $50 billion AI drug discovery revolution starts now.
And, of course, AI's applications in healthcare aren't limited to discovering viable drug candidates.
In fact, back in March, Nvidia (NVDA) held its GPU Technology Conference (GTC), an event for AI developers and enthusiasts. And the tech titan revealed that it's partnering with Johnson & Johnson (JNJ). The two will develop AI to help doctors perform surgery.
This is a huge development. After all, according to Nvidia, "J&J MedTech is in 80% of the world's operating rooms and trains more than 140,000 healthcare professionals each year." It's very likely that within the next decade, almost all surgeries will be at least partially automated by AI.
The potential that artificial intelligence holds for the healthcare industry is enormous. And as such, it's high time to bulk up your portfolio with top-of-the-line AI stocks.
Discover which high-octane stocks we're piling into. Get Positioned for Gains | | Sincerely,  | | Luke Lango
Editor, Hypergrowth Investing P.S. In the past few issues, I've alluded to Jonathan Rose, who has spent nearly two decades trading in the "pits" of the world's biggest exchanges. And next week, during a special Masters in Trading Summit, Jonathan will share the details behind one of the most consistent and lucrative trading strategies he discovered during his 15 years as a professional trader.
His method is based on a quantitative formula that has consistently predicted major market movements. In fact, over the past three years, 90.3% of the trades Jonathan recommended using this formula have been profitable . And at the event, you will learn how to use this formula to achieve gains as high as 197%, 317%, or even 1,147% — all in 30 days or less.
Sign up here now to join us on May 8th at 10 a.m. Eastern, as Jonathan pulls back the curtain and shares how he makes big profits, no matter which way the market moves. On the date of publication, Luke Lango did not have (either directly or indirectly) any positions in the securities mentioned in this article. | | | | |
Post a Comment
Post a Comment